Bromodeoxyuridine leaves evidence of prenatal exposure in the postnatal skeleton in CD-1 mice

Mice from two series of experiments (S1, S2) involving intraperitoneal (ip) injection of dams with 300 (High or H), 60 (Low or L), or 0 (VEH) mg 5'-bromodeoxyuridine (BUDR) per kilogram body weight (mg/kg) in water (15 mL/kg) on day seven (D7), day eight (D8), or in S2 only, day nine (D9) of gestation (9DPC), and untreated (UNTD) controls, were examined between 60 and 65 days postnatal (DPN) for 88 variations of the skeleton. In S1, 65 variants occurred, and in S2 there were 58 variants that occurred. Substantial numbers of significant differences (P less than 0.01) in frequency of occurrence (%) were seen in High dose only. The number of variants that differed from UNTD were 13, 13, 12, 15, and 11 in S1-D7H, S2-D7H, S1-D8H, S2-D8H, and S2-D9H, respectively; the average absolute difference in frequency among significantly affected variants was 16% to 20%. In the same order as above, 13, 12, 8, 10, and 9 variants differed significantly from VEH, and 9, 8, 7, 8, and 8 variants differed significantly from both UNTD and VEH. In contrast, 0, 0, 1, 1, and 0 variants differed from both UNTD and VEH in S1-D7L, S2-D7L, S1-D8L, S2-D8L, and S2-D9L, respectively. Agreement between the two series was good; 11 traits were affected in High dose litters in both series in at least 3 or 4 comparisons (compared with UNTD, VEH, in S1, S2).(ABSTRACT TRUNCATED AT 250 WORDS)